FLT3 and acute myeloid leukemia: FLT3 mutations are observed in nearly 30 to 35% of cases of recently diagnosed AML.67, 68, 69FLT3-TKD-type mutations develop in approximately 7 to 10% of cases of AML, whereas FLT3-ITD-type mutations develop in around 25% of patients of AML.70, 71Numerous FLT3 inhibitors consist of gilteritinib, crenolanib, sorafenib, sunitinib, quizartinib, and ponatinib.